FDA Commissioner Controversy Delays “Behind-The-Counter” Rx Precedent
Executive Summary
FDA appears to be ready to create a new class of "behind the counter" OTC drugs
You may also be interested in...
FDA Confirmation Process Hits A Roadblock: Time For Plan B?
Acting FDA Commissioner Lester Crawford's prospects for Senate confirmation appear to be in jeopardy after the Health Committee disclosed concerns about a conduct allegation lodged against the nominee
FDA Commissioner Nomination On Hold Pending Plan B Decision
Senate Health Committee Democrats are threatening to delay the confirmation of Lester Crawford as commissioner until the agency makes a decision about Barr's application to switch the emergency contraceptive Plan B to OTC status
Senate Health Democrats Press Crawford For Plan B Decision Timeline
Senate Health Committee Democrats are asking to meet with FDA Commissioner nominee Lester Crawford to discuss the Rx-to-OTC switch of emergency contraceptive Plan B prior to voting on his confirmation